Today, Euretos released a groundbreaking new application to find novel indications for known drug targets. Using the Indication Expansion function in the Euretos (re)Search application, researchers can find the most suitable alternative indications for an existing target by assessing simultaneously gene variance & expression, in depth target - disease interactions, available in-vitro & in-vivo experiments and known therapeutic agents for a specified mechanism of action.
“We provide life scientists with better answers to research questions. Faster.” says Aram Krol, Head of Product Management at Euretos. “Repurposing of approved drugs may seem an obvious, low risk approach to take. However, the need for personalized drug therapies that target increasingly complex disease mechanisms is making this far from easy. Using this workflow, researchers will find novel disease indications for existing targets that would otherwise not have been considered at all.”
One of the challenges in finding alternative indications is the enormous amount of potentially relevant information that needs to be assessed. The Euretos Knowledge Platform is unique in enabling this effectively where 10 relevant criteria can be evaluated simultaneously for all possible disease indications. Months of work are now compressed in minutes.
“It is the combination of the scope of our knowledge base, the detail of our date model and the on board analytics with the ability to easily verify each underlying statement, that provide unique capabilities to life scientists” says Krol. "Bioinformaticians have an API to their disposal that allows for flexible and easy integration of our knowledge in existing workflows."
The ability to guide researchers to discover novel therapeutic targets or biomarkers is regularly confirmed through recent scientific discoveries in various disease areas, such as: breast cancer, pancreatic cancer , chronic kidney disease and traumatic brain injury.